Evidence map›Paper›PMID 34230984›Full record

ArticleAnnals of hematology2021

Successful haploidentical transplantation using plasma exchange and post-transplantation cyclophosphamide for severe aplastic anemia patients with anti-human leukocyte antigen donor-specific antibodies.

Junjie Cao, Renzhi Pei, Pisheng Zhang, Xuhui Liu, Dong Chen, Xiaohong Du, Lieguang Chen, Tiantian Wang, Peipei Ye, Ying Lu

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Junjie CaoDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China. caojj99@126.com.ORCID http://orcid.org/0000-0001-5570-9007
Renzhi PeiDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Pisheng ZhangDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Xuhui LiuDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Dong ChenDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Xiaohong DuDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Lieguang ChenDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Tiantian WangDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Peipei YeDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Ying LuDepartment of Hematology, The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China.
Ningbo University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HSCT) has emerged as a novel strategy to treat patients suffering from severe aplastic anemia (SAA) who lack matched donors due to the availability and easy access to sources of donors. Anti-human leukocyte antigen donor-specific antibodies (DSAs) have been found to influence the outcome of Haplo-HSCT. Between March 2016 and March 2020, 7 SAA patients with DSAs underwent Haplo-HSCT in our center. We employed a modified protocol of post-transplantation cyclophosphamide and plasma exchange aiming to decrease the levels of DSAs. All 7 patients successfully achieved hematopoietic reconstruction. The median follow-up is 31 (range, 8 to 45) months. They survived and were transfusion-independent in the absence of clonality. No occurrence of primary or secondary graft failure has been noted among any of the patients. There was no severe acute and chronic GVHD occurred. This protocol is effective for Haplo-HSCT in SAA patients with DSAs, which provides an option for the SAA patients without other alternative donor.

Indexed as

AdultAnemia, AplasticAntibodiesCyclophosphamideFemaleHematopoietic Stem Cell TransplantationHLA AntigensHumansImmunosuppressive AgentsMaleMiddle AgedPlasma ExchangeTissue DonorsTransplantation, HaploidenticalAntibodiesCyclophosphamideHLA AntigensImmunosuppressive AgentsAplastic anemiaHaploidenticalPlasma exchangePost-transplantation cyclophosphamideTransplantation

Identifiers

PMID34230984
OpenAlexW3180196234

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.